TSX News -
Trillium Expands Clinical Trial With TTI-621 to Include Combination With PD-1 Blockade
TORONTO, ONTARIO–(Marketwired – June 7, 2017) – Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company, today announced that based […]